Skip to main content
Erschienen in: Der Urologe 12/2012

01.12.2012 | Leitthema

Neue Behandlungskonzepte von Symptomen des unteren Harntraktes beim Mann

verfasst von: L.F. Arenas da Silva, M. Schönthaler, F. Cruz, C. Gratzke, J. Zumbe, A. Stenzl, B. Amend, Prof. Dr. K.-D. Sievert

Erschienen in: Die Urologie | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Als Goldstandard in der medikamentösen Therapie von Patienten mit Beschwerden des unteren Harntraktes („lower urinary tract symptoms“, LUTS) werden α1-Adrenozeptorblocker und 5α-Reduktaseinhibitoren sowie deren Kombination angesehen. Darüber hinaus kommen Anticholinergika bei Patienten mit überwiegenden Speicherstörungen zum Einsatz, während Phosphodiesterase-5-Hemmer ihr primäres Einsatzgebiet bei Patienten mit LUTS und erektiler Dysfunktion finden. In den letzten Jahren wurde die Suche nach neuen Therapieverfahren intensiviert. Vor allem intraprostatische Injektionstherapien (Botulinumtoxin A, NX-1207, PRX302) und innovative interventionelle Techniken (UroLift®) werden in Hinblick auf ihre Wirkung bei Patienten mit LUTS getestet und scheinen dabei wirksam und sicher zu sein. Besonderes Augenmerk sollte dabei auf den Zusammenhang von LUTS und sexuellen Funktionsstörungen gelegt werden.
Literatur
1.
Zurück zum Zitat Djavan B, Waldert M, Ghawidel C, Marberger M (2004) Benign prostatic hyperplasia progression and its impact on treatment. Curr Opin Urol 14:45–50PubMedCrossRef Djavan B, Waldert M, Ghawidel C, Marberger M (2004) Benign prostatic hyperplasia progression and its impact on treatment. Curr Opin Urol 14:45–50PubMedCrossRef
2.
Zurück zum Zitat Bushman W (2009) Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 36:403–415PubMedCrossRef Bushman W (2009) Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 36:403–415PubMedCrossRef
3.
Zurück zum Zitat Krambeck AE, Jacobson DJ, McGree ME et al (2012) Effectiveness of medical and surgical therapies for lower urinary tract symptoms in the community setting. BJU Int (Epub ahead of print) Krambeck AE, Jacobson DJ, McGree ME et al (2012) Effectiveness of medical and surgical therapies for lower urinary tract symptoms in the community setting. BJU Int (Epub ahead of print)
4.
Zurück zum Zitat Hyman MJ, Groutz A, Blaivas JG (2001) Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 166:550–553PubMedCrossRef Hyman MJ, Groutz A, Blaivas JG (2001) Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 166:550–553PubMedCrossRef
5.
Zurück zum Zitat Barkin J, Giddens J, Incze P et al (2012) UroLift system for relief of prostate obstruction under local anesthesia. Can J Urol 19:6217–6222PubMed Barkin J, Giddens J, Incze P et al (2012) UroLift system for relief of prostate obstruction under local anesthesia. Can J Urol 19:6217–6222PubMed
6.
Zurück zum Zitat Al-Ansari A, Younes N, Sampige VP et al (2010) GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. Eur Urol 58:349–355PubMedCrossRef Al-Ansari A, Younes N, Sampige VP et al (2010) GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. Eur Urol 58:349–355PubMedCrossRef
7.
Zurück zum Zitat Melick HH van, Venrooij GE van, Boon TA (2003) Laser prostatectomy in patients on anticoagulant therapy or with bleeding disorders. J Urol 170:1851–1855PubMedCrossRef Melick HH van, Venrooij GE van, Boon TA (2003) Laser prostatectomy in patients on anticoagulant therapy or with bleeding disorders. J Urol 170:1851–1855PubMedCrossRef
8.
Zurück zum Zitat McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338:557–563PubMedCrossRef McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338:557–563PubMedCrossRef
9.
Zurück zum Zitat Strittmatter F, Madersbacher S, Stief CG, Gratzke C (2012) Medicinal therapy of benign prostate syndrome. Urologe A 51:1125–1136PubMedCrossRef Strittmatter F, Madersbacher S, Stief CG, Gratzke C (2012) Medicinal therapy of benign prostate syndrome. Urologe A 51:1125–1136PubMedCrossRef
10.
Zurück zum Zitat Tatemichi S, Akiyama K, Kobayashi M et al (2006) A selective alpha1 A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J Urol 176:1236–1241PubMedCrossRef Tatemichi S, Akiyama K, Kobayashi M et al (2006) A selective alpha1 A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J Urol 176:1236–1241PubMedCrossRef
11.
Zurück zum Zitat Prieto L, Romero J, Lopez C et al (2008) Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urol Int 81:66–71PubMedCrossRef Prieto L, Romero J, Lopez C et al (2008) Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urol Int 81:66–71PubMedCrossRef
12.
Zurück zum Zitat Wilt TJ, Macdonald R, Rutks I (2011) WITHDRAWN: Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev:CD002081 Wilt TJ, Macdonald R, Rutks I (2011) WITHDRAWN: Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev:CD002081
13.
Zurück zum Zitat Nejishima H, Yamamoto N, Suzuki M et al (2012) Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia. Prostate 72(14):1580–1587PubMedCrossRef Nejishima H, Yamamoto N, Suzuki M et al (2012) Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia. Prostate 72(14):1580–1587PubMedCrossRef
14.
Zurück zum Zitat Wang C (2010) Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 20:49–54PubMedCrossRef Wang C (2010) Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 20:49–54PubMedCrossRef
15.
Zurück zum Zitat Angulo J, Cuevas P, Fernandez A et al (2012) Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. J Sex Med 9(9):2293–2306PubMedCrossRef Angulo J, Cuevas P, Fernandez A et al (2012) Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. J Sex Med 9(9):2293–2306PubMedCrossRef
16.
Zurück zum Zitat Gacci M, Corona G, Salvi M et al (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61:994–1003PubMedCrossRef Gacci M, Corona G, Salvi M et al (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61:994–1003PubMedCrossRef
17.
Zurück zum Zitat Oelke M, Giuliano F, Mirone V et al (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61:917–925PubMedCrossRef Oelke M, Giuliano F, Mirone V et al (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61:917–925PubMedCrossRef
18.
Zurück zum Zitat Egerdie RB, Auerbach S, Roehrborn CG et al (2012) Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 9:271–281PubMedCrossRef Egerdie RB, Auerbach S, Roehrborn CG et al (2012) Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 9:271–281PubMedCrossRef
19.
Zurück zum Zitat Rick FG, Schally AV, Block NL et al (2011) LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 71:736–747PubMedCrossRef Rick FG, Schally AV, Block NL et al (2011) LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 71:736–747PubMedCrossRef
20.
Zurück zum Zitat Siejka A, Schally AV, Block NL, Barabutis N (2010) Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int 106:1382–1388PubMedCrossRef Siejka A, Schally AV, Block NL, Barabutis N (2010) Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int 106:1382–1388PubMedCrossRef
21.
Zurück zum Zitat Debruyne F, Tzvetkov M, Altarac S, Geavlete PA (2010) Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Urology 76:927–933PubMedCrossRef Debruyne F, Tzvetkov M, Altarac S, Geavlete PA (2010) Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Urology 76:927–933PubMedCrossRef
22.
Zurück zum Zitat Wong WC, Wong EL, Li H et al (2012) Isoflavones in treating watchful waiting benign prostate hyperplasia: a double-blinded, randomized controlled trial. J Altern Compl Med 18:54–60CrossRef Wong WC, Wong EL, Li H et al (2012) Isoflavones in treating watchful waiting benign prostate hyperplasia: a double-blinded, randomized controlled trial. J Altern Compl Med 18:54–60CrossRef
23.
Zurück zum Zitat MacDonald R, Tacklind JW, Rutks I, Wilt TJ (2012) Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int 109:1756–1761PubMedCrossRef MacDonald R, Tacklind JW, Rutks I, Wilt TJ (2012) Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int 109:1756–1761PubMedCrossRef
24.
Zurück zum Zitat Crescioli C, Maggi M, Luconi M et al (2002) Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells. Prostate 50:15–26PubMedCrossRef Crescioli C, Maggi M, Luconi M et al (2002) Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells. Prostate 50:15–26PubMedCrossRef
25.
Zurück zum Zitat Crescioli C, Ferruzzi P, Caporali A et al (2004) Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 150:591–603PubMedCrossRef Crescioli C, Ferruzzi P, Caporali A et al (2004) Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 150:591–603PubMedCrossRef
26.
Zurück zum Zitat Crescioli C, Ferruzzi P, Caporali A et al (2003) Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. Endocrinology 144:3046–3057PubMedCrossRef Crescioli C, Ferruzzi P, Caporali A et al (2003) Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. Endocrinology 144:3046–3057PubMedCrossRef
27.
Zurück zum Zitat Colli E, Rigatti P, Montorsi F et al (2006) BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol 49:82–86PubMedCrossRef Colli E, Rigatti P, Montorsi F et al (2006) BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol 49:82–86PubMedCrossRef
28.
Zurück zum Zitat Zahariou A, Karamouti M, Karagiannis G, Papaioannou P (2008) Maximal bladder capacity is a positive predictor of response to desmopressin treatment in patients with MS and nocturia. Int Urol Nephrol 40:65–69PubMedCrossRef Zahariou A, Karamouti M, Karagiannis G, Papaioannou P (2008) Maximal bladder capacity is a positive predictor of response to desmopressin treatment in patients with MS and nocturia. Int Urol Nephrol 40:65–69PubMedCrossRef
29.
Zurück zum Zitat Goya N, Ishikawa N, Ito F et al (2004) Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results. J Urol 172:1017–1020PubMedCrossRef Goya N, Ishikawa N, Ito F et al (2004) Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results. J Urol 172:1017–1020PubMedCrossRef
30.
Zurück zum Zitat Grise P, Plante M, Palmer J et al (2004) Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur Urol 46:496–502PubMedCrossRef Grise P, Plante M, Palmer J et al (2004) Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur Urol 46:496–502PubMedCrossRef
31.
Zurück zum Zitat Maria G, Brisinda G, Civello IM et al (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62:259–265PubMedCrossRef Maria G, Brisinda G, Civello IM et al (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62:259–265PubMedCrossRef
32.
Zurück zum Zitat Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA (1998) Botox-induced prostatic involution. Prostate 37:44–50PubMedCrossRef Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA (1998) Botox-induced prostatic involution. Prostate 37:44–50PubMedCrossRef
33.
Zurück zum Zitat Chuang YC, Chiang PH, Huang CC et al (2005) Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66:775–779PubMedCrossRef Chuang YC, Chiang PH, Huang CC et al (2005) Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66:775–779PubMedCrossRef
34.
Zurück zum Zitat Chuang YC, Chiang PH, Yoshimura N et al (2006) Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 98:1033–1337PubMedCrossRef Chuang YC, Chiang PH, Yoshimura N et al (2006) Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 98:1033–1337PubMedCrossRef
35.
Zurück zum Zitat Kuo HC (2005) Prostate botulinum A toxin injection – an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 65:670–674PubMedCrossRef Kuo HC (2005) Prostate botulinum A toxin injection – an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 65:670–674PubMedCrossRef
36.
Zurück zum Zitat Guercini F, Pajoncini C, Bard R et al (2005) Echoguided drug infiltration in chronic prostatitis: results of a multi-centre study. Arch Ital Urol Androl 77:87–92PubMed Guercini F, Pajoncini C, Bard R et al (2005) Echoguided drug infiltration in chronic prostatitis: results of a multi-centre study. Arch Ital Urol Androl 77:87–92PubMed
37.
Zurück zum Zitat Crawford ED, Hirst K, Kusek JW et al (2011) Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol 186:965–970PubMedCrossRef Crawford ED, Hirst K, Kusek JW et al (2011) Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol 186:965–970PubMedCrossRef
38.
Zurück zum Zitat Silva J, Silva C, Saraiva L et al (2008) Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol 53:153–159PubMedCrossRef Silva J, Silva C, Saraiva L et al (2008) Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol 53:153–159PubMedCrossRef
39.
Zurück zum Zitat Silva J, Pinto R, Carvallho T et al (2009) Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat. Eur Urol 56:134–140PubMedCrossRef Silva J, Pinto R, Carvallho T et al (2009) Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat. Eur Urol 56:134–140PubMedCrossRef
40.
Zurück zum Zitat Hamidi Madani A, Enshaei A, Heidarzadeh A et al (2012) Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates. World J Urol (Epub ahead of print) Hamidi Madani A, Enshaei A, Heidarzadeh A et al (2012) Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates. World J Urol (Epub ahead of print)
41.
Zurück zum Zitat Silva J, Pinto R, Carvalho T et al (2011) Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int 107:1950–1954PubMedCrossRef Silva J, Pinto R, Carvalho T et al (2011) Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int 107:1950–1954PubMedCrossRef
42.
Zurück zum Zitat Chuang YC, Tu CH, Huang CC et al (2006) Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol 6:12PubMedCrossRef Chuang YC, Tu CH, Huang CC et al (2006) Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol 6:12PubMedCrossRef
43.
Zurück zum Zitat Shore N (2010) NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 19:305–310PubMedCrossRef Shore N (2010) NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 19:305–310PubMedCrossRef
44.
Zurück zum Zitat Singh R, Browning JL, Abi-Habib R et al (2007) Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anticancer Drugs 18:809–816PubMedCrossRef Singh R, Browning JL, Abi-Habib R et al (2007) Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anticancer Drugs 18:809–816PubMedCrossRef
45.
Zurück zum Zitat Denmeade SR, Egerdie B, Steinhoff G et al (2011) Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 59:747–754PubMedCrossRef Denmeade SR, Egerdie B, Steinhoff G et al (2011) Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 59:747–754PubMedCrossRef
46.
Zurück zum Zitat Chin PT, Bolton DM, Jack G et al (2012) Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79:5–11PubMedCrossRef Chin PT, Bolton DM, Jack G et al (2012) Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79:5–11PubMedCrossRef
47.
Zurück zum Zitat Woo HH, Bolton DM, Laborde E et al (2012) Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 9:568–575PubMedCrossRef Woo HH, Bolton DM, Laborde E et al (2012) Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 9:568–575PubMedCrossRef
48.
Zurück zum Zitat Woo HH, Chin PT, McNicholas TA et al (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108:82–88PubMedCrossRef Woo HH, Chin PT, McNicholas TA et al (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108:82–88PubMedCrossRef
Metadaten
Titel
Neue Behandlungskonzepte von Symptomen des unteren Harntraktes beim Mann
verfasst von
L.F. Arenas da Silva
M. Schönthaler
F. Cruz
C. Gratzke
J. Zumbe
A. Stenzl
B. Amend
Prof. Dr. K.-D. Sievert
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Die Urologie / Ausgabe 12/2012
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-012-3032-1

Weitere Artikel der Ausgabe 12/2012

Der Urologe 12/2012 Zur Ausgabe

URO-Telegramm

URO-Telegramm

Mitteilungen der DGU

Mitteilungen der DGU

Mitteilungen der DGU

Termine

Aktive Prostata-Überwachung lohnt sich für die meisten

13.06.2024 Prostatakarzinom Nachrichten

Für die meisten Männer mit einem Prostatakarzinom und geringem Progressionsrisiko ist die aktive Überwachung eine gute Wahl: Nach zehn Jahren ist mehr als die Hälfte immer noch progressionsfrei, und weniger als 2% haben Metastasen entwickelt.

HPV-Impfung schützt auch Männer vor Krebs

12.06.2024 ASCO 2024 Kongressbericht

Die HPV-Impfung wird für Mädchen wie Jungen vorrangig empfohlen, um Zervixkarzinome bei Frauen zu verhindern. Doch auch andere HPV-assoziierte Krebserkrankungen werden reduziert.

Nach Krebstherapie mit Cisplatin auf Schwerhörigkeit screenen!

11.06.2024 Hodenkarzinom Nachrichten

Wer zur Behandlung einer Krebserkrankung Cisplatin erhalten hat, sollte regelmäßig das Hörvermögen überprüfen lassen und strikt auf die Cholesterinwerte achten. So das Fazit einer Longitudinalstudie mit Hodenkrebspatienten.

Nierenspende stellt kein Risiko für Hypertonie dar

07.06.2024 Nierentransplantation Nachrichten

Wer im Zuge einer Lebendspende eine seiner Nieren an eine Person im Nierenversagen weitergibt, muss nicht fürchten, sich damit ein erhöhtes Hypertonierisiko einzuhandeln. Auch Albuminurie tritt nicht häufiger auf, wie eine Studie zeigt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.